As we enter a new year, Scrip takes a look at the five biggest themes that got the most hits from our readers over the last 12 months.

For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.

Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.

Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.